海辰药业(300584) - 2025 Q3 - 季度财报

Revenue and Profit - The company's revenue for Q3 2025 reached ¥162,954,321.51, representing a year-on-year increase of 31.45%[5] - Net profit attributable to shareholders was ¥3,520,760.91, up 4.15% compared to the same period last year[5] - Operating revenue increased by 30.80% to ¥471,526,892.93 compared to ¥360,497,824.16 in the same period last year, primarily due to growth in the injection of hydrochloride lanadelumab business[9] - Total operating revenue for the current period reached ¥471,526,892.93, an increase from ¥360,497,824.16 in the previous period, representing a growth of approximately 30.9%[17] - Net profit for the current period was ¥32,194,633.14, compared to ¥28,116,806.63 in the previous period, reflecting an increase of approximately 14.8%[18] - Total comprehensive income for the period attributable to the parent company was CNY 32,678,503.32, compared to CNY 28,116,806.63 in the previous period, representing an increase of approximately 15.5%[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,483,375,637.55, an increase of 1.29% from the end of the previous year[5] - The company’s total assets increased to ¥1,483,375,637.55 from ¥1,464,546,955.74, marking a growth of about 1.3%[16] - The company’s total liabilities decreased to ¥410,137,814.43 from ¥426,373,270.65, a reduction of approximately 3.8%[16] - The total equity attributable to shareholders increased to ¥1,043,329,086.59 from ¥1,022,936,243.51, reflecting a growth of about 1.98%[16] Cash Flow - Cash flow from operating activities for the year-to-date reached ¥58,486,668.79, up 33.09%[5] - Net cash flow from operating activities increased by 33.09% to ¥58,486,668.79 from ¥43,945,167.75, attributed to higher cash inflows from product sales[9] - Cash inflow from operating activities totaled CNY 477,727,059.54, compared to CNY 398,528,192.31 in the previous period, marking an increase of about 19.9%[21] - Cash outflow from operating activities was CNY 419,240,390.75, up from CNY 354,583,024.56, which is an increase of approximately 18.2%[22] - The ending balance of cash and cash equivalents was CNY 76,144,155.15, compared to CNY 38,197,993.87 in the previous period, indicating a significant increase[22] Expenses - Management expenses rose by 64.56% to ¥104,692,101.85 from ¥63,620,585.66, mainly due to the inclusion of pre-research expenses for unapproved R&D projects[9] - Research and development expenses for the current period were ¥31,204,448.18, down from ¥34,268,297.38, a decrease of about 9.5%[18] Other Financial Metrics - The basic earnings per share for the period was ¥0.0293, reflecting a 3.90% increase year-on-year[5] - Basic and diluted earnings per share increased to CNY 0.2723 from CNY 0.2343, reflecting a growth of about 16.5%[19] - The company reported a significant increase of 469.63% in other receivables, totaling ¥466,728.92, attributed to increased receivables and reserves[8] - The company reported an investment loss of ¥2,763,924.66, primarily due to investments made by the subsidiary Anqing Huichen[9] - The total deferred tax liabilities decreased by 32.40% to ¥8,436,277.90 from ¥12,480,575.90, mainly due to the reduction in deferred tax expenses recognized at the end of the previous year[9] Financing Activities - The net cash flow from financing activities decreased by 414.57% to -¥21,988,756.49 from ¥6,990,069.18, reflecting a reduction in financing loan amounts compared to the previous year[9] - Cash inflow from financing activities was CNY 203,100,000.00, down from CNY 251,100,483.33, representing a decrease of about 18.9%[22] - The company raised CNY 15,000,000.00 from minority shareholders during the financing activities[22] Other Information - The company experienced a 91.90% decrease in employee compensation payable, amounting to ¥352,240.86, due to the distribution of annual bonuses[8] - The third quarter financial report was not audited, which may impact the reliability of the reported figures[23]